| Name | Title | Contact Details |
|---|
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.
A certified minority-owned business, SourceMark continues to focus on your needs to improve the lives of all patients, customers, and healthcare providers. Our clinical advisory groups are personally involved with the continued improvement of current p...
RX Institutional Services is a Youngstown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elixir, (formerly EnvisionRxOptions) a wholly owned subsidiary of Rite Aid, is a pharmacy benefits and services company with the unique ability to optimize the full pharmacy care experience.
Hemarus is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.